Latest Commercialization News

Carnaby Resources has reported a game-changing drill result at its Trek 1 prospect, intersecting 7m at 9.3% copper equivalent, significantly extending known mineralisation beyond the current resource estimate.

Starpharma has entered a significant collaboration with Genentech to develop dendrimer-drug conjugates for oncology, securing an upfront payment and potential milestone earnings exceeding half a billion dollars.

Starpharma has entered a landmark collaboration with Genentech to develop innovative cancer therapies using its proprietary DEP® platform, securing $5.5 million upfront and potential milestones exceeding $560 million.

Charger Metals has secured approvals for a significant 4,600m drilling campaign at its Lake Johnston Lithium and Gold Project, fully funded by Rio Tinto Exploration. This move aims to build on recent resource milestones and explore new lithium targets in Western Australia.

Core Energy Minerals has appointed Anthony Greenaway as Managing Director, aiming to leverage his extensive exploration expertise to advance its uranium and rare earth projects in South Australia and Brazil.

PYC Therapeutics has restructured its Board and executive team to steer the company through pivotal clinical milestones expected by the end of 2027. The changes signal a strategic push toward late-stage development of its RNA-based drug candidates.

HealthCo Healthcare & Wellness REIT has collected all outstanding rent from Healthscope and extended a rent deferral to support the ongoing sale process, while suspending distributions to preserve liquidity.

LTR Pharma has acquired a one-third equity stake in LevOmega Pty Ltd at no cost to shareholders, positioning itself in the growing pharmaceutical-grade omega-3 sector. This strategic move complements LTR’s existing intranasal pharmaceutical portfolio and aligns with its innovation-driven growth strategy.

Brazilian Critical Minerals has reported sustained high-grade rare earth element recovery from its in-situ recovery trials at the Ema Project, with pregnant leach solution grades exceeding 5,700 ppm TREO and strong magnet rare earth oxide content.

EVE Health Group has begun distributing Dyspro™, a novel cannabinoid-based treatment for dysmenorrhoea and endometriosis, through a national telehealth partnership. This launch targets a significant unmet need in women’s health with a growing global market.

Everlast Minerals Ltd has issued a Replacement Prospectus for a $4-6 million ASX IPO to fund its mineral sands projects in Bangladesh, focusing on advancing the Gaibandha project towards commercial production.

ChemX Materials Limited has entered voluntary administration following a turbulent quarter marked by convertible note amendments, a trading suspension, and ongoing funding challenges.